Technology
Health
Medical

Genmab

$17.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-0.79%) Today
-$0.14 (-0.79%) Today

Why Robinhood?

You can buy or sell Genmab and other stocks, options, ETFs, and crypto commission-free!

About

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Read More Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. GMXAY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
377
Headquarters
Copenhagen, Capital Region
Founded
1999
Market Cap
2.18B
Price-Earnings Ratio
9.38
Dividend Yield
0.00
Average Volume
50.60K
High Today
$17.74
Low Today
$17.54
Open Price
$17.74
Volume
4.13K
52 Week High
$21.68
52 Week Low
$12.10

Collections

Technology
Health
Medical
Biotechnology
Therapy
Cancer Prevention
2013 IPO
Europe (Non-UK)

News

Simply Wall StMar 14

Investors Who Bought Genmab (CPH:GEN) Shares Five Years Ago Are Now Up 367%

Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality companies can see their share prices grow by huge amounts. Don’t believe it? Then look at the Genmab A/S (CPH:GEN) share price. It’s 367% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. It’s also up 17% in about a month. This could be related to the recent financial results that were recently released – you could check the most recent d...

12
PR NewswireMar 12

Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

RARITAN, N.J., March 12, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The sBLA, based upon data from the Phase 3 ...

1
Simply Wall StMar 4

Genmab A/S (CPH:GEN) Has Attractive Fundamentals

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Genmab A/S (CPH:GEN), it is a company with great financial health as well as a a strong track record of performance. In the following section, I expand a bit more on these key aspects. For those interested in digger a bit deeper into my commentary, read the full report on Genmab here. Flawless ...

11
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.